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Abstract
Objective: Multiple sclerosis (MS) is a disease of the central nervous system
with marked heterogeneity in several aspects including pathological processes.
Based on infiltrating immune cells, deposition of humoral factors and loss of
oligodendrocytes and/or myelin proteins, four lesion patterns have been
described. Pattern II is characterized by antibody and complement deposition
in addition to T-cell infiltration. MS is considered a T-cell-mediated disease,
but until now the study of pathogenic T cells has encountered major challenges,
most importantly the limited access of brain-infiltrating T cells. Our objective
was to identify, isolate, and characterize brain-infiltrating clonally expanded T
cells in pattern II MS lesions. Methods: We used next-generation sequencing to
identify clonally expanded T cells in demyelinating pattern II brain autopsy
lesions, subsequently isolated these as T-cell clones from autologous cerebrospi-
nal fluid and functionally characterized them. Results: We identified clonally
expanded CD8+ but also CD4+ T cells in demyelinating pattern II lesions and
for the first time were able to isolate these as live T-cell clones. The functional
characterization shows that T cells releasing Th2 cytokines and able to provide
B cell help dominate the T-cell infiltrate in pattern II brain lesions. Interpreta-
tion: Our data provide the first functional evidence for a putative role of Th2/
Tc2 cells in pattern II MS supporting the existence of this pathogenic pheno-
type and questioning the protective role that is generally ascribed to Th2 cells.
Our observations are important to consider for future treatments of pattern II
MS patients.
Introduction
The etiology of multiple sclerosis (MS) involves a com-
plex genetic trait1,2 and environmental risk factors.3 The
pathomechanisms of MS include inflammation, de- and
remyelination, secondary neurodegeneration, astrogliosis,
and metabolic alterations. This complex etiology and
pathogenesis translate into marked heterogeneity with
respect to clinical presentation, imaging, disease course
and response to treatment, as well as composition of
tissue lesions. More than 10 years ago, pathologists began
to dissect MS heterogeneity by characterizing MS brain
lesions initially in cross-sectional studies4 and more
recently longitudinally.5 They demonstrated that lesion
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composition is homogeneous in a single patient and pre-
served over time, but varies interindividually. Based on
infiltrating immune cells, deposition of humoral factors
and loss of oligodendrocyte and/or myelin proteins, four
lesion patterns have been defined: pattern I, macrophage
and T-cell mediated; pattern II, macrophage, T-cell and
antibody/complement mediated; pattern III, characterized
by a distal oligodendrogliopathy and the less frequent pat-
tern IV suggestive of primary oligodendrocyte degenera-
tion. Despite the observation that patients with pattern II
respond favorably to therapeutic plasma exchange,6 there
is so far no functional data that support these four pat-
terns or provide mechanistic insight.
MS is considered a CD4+ T-cell-mediated autoimmune
disease based on the fact that the HLA-DR15 haplotype is
the strongest genetic risk factor and that CD4+ T cells are
able to induce a demyelinating disease similar to MS in
several experimental animal models.7 However, the pre-
disposition conferred by the HLA-A*0301 allele and pro-
tection by the HLA-A*02011,8 supported by evidence in
experimental animal models,9 imply that CD8+ T cells
also play a role. In humans, two approaches have been
employed to study potentially pathogenic T cells in MS.
The first focused on circulating T cells specific for myelin.
Several interesting observations emerged from these stud-
ies including that myelin-specific CD4+ T cells have
higher functional avidity in MS patients,10 often do not
express the costimulatory molecule CD2811 and frequently
have a T-helper 1 (Th1) phenotype.12 Based on the ratio-
nale that disease-relevant T cells may express a limited
number of T-cell receptors (TCR) or skewed reper-
toire,13–15 the second approach used the TCR as a guide
to identify relevant cells in brain tissue. This second
approach, not biased by assumptions about autoantigens,
demonstrated greater abundance and invasiveness of
CD8+ T cells in acute and chronic MS lesions16,17 and, by
using TCR analysis of single tissue-infiltrating T cells, also
preferential clonal expansions.18–20 The main limitation of
this approach has been the inability to provide informa-
tion regarding functional phenotype and specificity since
only frozen autopsy brain tissue was available. Despite
efforts to “revive” single brain-infiltrating T cells by
expressing TCR a- and b chains in recombinant systems,
the identification of the correct pairs remains an impor-
tant challenge. Furthermore, even if this approach is suc-
cessful it will only allow studying the specificity, but not
the functional phenotype.
To overcome these limitations, we have used here next-
generation sequencing to identify clonally expanded CD8+
and CD4+ T cells that infiltrate pattern II MS brain lesions
from autopsy tissue. Subsequently, we have isolated these
T cells from autologous cerebrospinal fluid (CSF)-infiltrating
T cells and functionally characterized them.
Patients and Methods
Patient material
Clinical case I
In June 2003, a 31-year-old woman reported for the first
time dizziness and gait disturbance. One year later, in
May 2004 she had an episode of unsteady gait, double
vision and fatigue. After high dose of methylprednisolone
therapy she improved temporarily, but 2 months later she
significantly deteriorated showing restricted walking dis-
tance (500–1000 m). A diagnosis of relapsing-remitting
multiple sclerosis (RRMS) was made August 2004 based
on typical MRI findings and CSF oligoclonal bands. After
these first attacks, she showed steady worsening. In Janu-
ary 2005, her gait had deteriorated; she showed saccadic
speech and blurred vision with an expanded disability sta-
tus scale (EDSS) score of 3. One year later, she com-
plained of fatigue, showed cerebellar ataxia, and her
walking distance was reduced (500 m) with an EDSS of 4.
Despite treatment with mitoxantrone (May and August
2006) her gait, ataxia and oculomotor signs deteriorated
further, and in May 2007 she had an EDSS of 5.5. In May
2008 she had worsened further and showed dysphagia
and dysarthria with an EDSS of 8.0. Due to her rapid
progression in the previous months, she received alloge-
neic mesenchymal stem cell transplantation and was
prepared for autologous hematopoietic stem cell trans-
plantation with cyclophosphamide and G-CSF. Unfortu-
nately, she died before transplantation could be
performed (Fig. S1A).
MRI images from 2004 showed extensive periventricu-
lar lesions, multiple lesions in the medulla oblongata and
cerebellar peduncle, and weak gadolinium enhancement.
MRI images from 2006 showed progression with
increased lesion load and multiple necrotic defects and no
gadolinium enhancement. The last MRI images from May
2008 showed further progression with massive confluent
supra- and infratentorial lesion load, gadolinium
enhancement in mesencephalic, splenial, and periventricu-
lar lesions, and substantial global atrophy (Fig. S1B).
HLA-class I and II types are: A*32:01, A*33:01, B*14:02,
B*51:01, DRB1*15:01, DRB5* 01:01, DQB1*06:02 and
DQA1*01:02.
CSF and CSF-derived mononuclear cells were obtained
directly from a diagnostic spinal tap performed on the 30
May 2008. CSF fluid was separated by centrifugation and
immediately frozen at 80°C. CSF cells were expanded
in vitro (see below). Peripheral blood mononuclear cells
(PBMCs) were separated by Ficoll density gradient centri-
fugation (PAA, Pasching, Austria) from blood obtained
on 26 May 2008. Serum from this time-point was also
obtained and frozen at 80°C. Autopsy brain tissue was
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fixed in chilled 4% buffered paraformaldehyde for paraf-
fin embedding and sections of mirror blocks frozen for
DNA/RNA extractions. Both CSF and PBMCs were
obtained before allogeneic mesenchymal stem cell trans-
plantation (performed the 2 June 2008) and before the
patient was prepared for autologous hematopoietic stem
cell transplantation with cyclophosphamide (administered
the 16 June 2008) and G-CSF (administered the 21 June
2008). Furthermore, the patient did not receive any pre-
treatment prior to intravenous administration of the allo-
geneic mesenchymal stem cells.
Clinical case II
CSF and CSF-derived mononuclear cells were obtained
directly from a 40-year-old female patient with secondary
progressive MS (SPMS; EDSS 6), who after 3 months
therapy with humanized anti-VLA4 monoclonal antibody
(Natalizumab) and 1 year Fingolimod therapy underwent
a diagnostic brain biopsy because of suspected progressive
multifocal leukoencephalopathy (PML). Neuropathologi-
cal examination at the Department of Neuropathology,
University of G€ottingen, Germany, refuted differential
diagnoses of PML or tumor and confirmed MS with early
active demyelination showing pattern III pathology.
The study of these two clinical cases was approved by
the Ethik Kommission der €Arztekammer Hamburg, pro-
tocol No. 2758, and informed consent was obtained from
the patient or relatives.
Neuropathology and immunohistochemistry
Formalin-fixed, paraffin-embedded (FFPE) 1 lm thick
sections were stained with hematoxylin and eosin, Luxol-
fast blue/periodic acid–Schiff and Bielschowsky’s silver
impregnation. Immunohistochemical staining was per-
formed (avidin–biotin based) using the following antibod-
ies: anti-MAG (myelin-associated glycoprotein, polyclonal
pc, gift of Prof. Richter-Landsberg, Oldenburg, Germany),
anti-MOG (myelin oligodendrocyte glycoprotein, pc, Prof.
Merkler, University of Geneva, Switzerland), anti-CNPase
(2030-cyclic nucleotide 30phosphodiesterase, clone SMI91,
Sternberger Monoclonals, Lutherville, MD), anti-PLP
(proteolipid protein, clone Plpc1, Serotec, Oxford, U.K.),
anti-MBP (myelin basic protein protein, pc, Dako, Glost-
rup, Denmark), and antibodies directed against the termi-
nal complement complex (pc, kindly provided by Prof.
Morgan, Cardiff, U.K.). Positive controls and negative
controls (omitting the primary antibody) were used for
all antibodies.
Lesions were first staged according to demyelinating
activity based on published criteria.21 Early active lesions
contained myelin-laden macrophages immunoreactive for
minor (CNPase, MOG, MAG) and major (MBP, PLP)
myelin proteins, whereas late active lesions contained
macrophages immunoreactive for major myelin proteins
only. Inactive areas lacked myelin-
laden macrophages. Early active demyelination is an abso-
lute prerequisite for immunopattern classification. Early
active lesions were than classified into immunopathologi-
cal patterns I–IV according to published criteria.4
Tissue sections were analyzed using an Olympus BX41
microscopy equipped with a DP20 camera (Olympus
Optical Co, Ltd., Hamburg, Germany).
Cell isolation, cell culture and cell
stimulation
Cell sorting
All cell populations were sorted using a FACSAriaTM III
(BD Biosciences, Franklin Lakes, NJ), and only prepara-
tions with a purity of >95% were used for further experi-
ments. Memory CD4+ and CD8+ T cells were sorted from
peripheral blood after staining with the following anti-
bodies: anti-CD3-PE (Biolegend, San Diego, CA), anti-
CD4-APC (eBiosciences, San Diego, CA), anti-CD8-Paci-
fic Blue (Biolegend) and anti-CD45RO FITC (Biolegend).
T cells expressing specific Vb families were sorted from
bulk CSF Phytohaemagglutinin (PHA)-expanded cells
after staining with the corresponding TCR Vb-specific
antibodies22 (Beckman Coulter, Nyon, Switzerland). B
cells from peripheral blood were sorted after staining with
anti-CD19-Pacific Blue (BD).
Expansion of CSF-derived Cells
CSF-derived mononuclear cells were expanded as previ-
ously reported.23,24 Briefly, 2000 cells per well were seeded
in 96-well U-botton microtiter plates together with
2 9 105 nonautologous, irradiated PBMC (45 Gy), 1 lg/
mL of PHA-L (Sigma, St Louis, MO), and IL-2 superna-
tant (20009 diluted) (kindly provided by Dr. Sallusto,
Institute for Research in Biomedicine, Bellinzona, Switzer-
land). Medium consisted of IMDM (PAA) containing
100 U/mL penicillin/streptomycin (PAA), 50 lg/mL gen-
tamicin (BioWhittaker, Cambrex, East Rutherford, NJ,
USA), 2 mmol/L L-glutamine (GIBCO, Invitrogen, Wal-
tham, MA, USA) and 5% heat-decomplemented human
serum (PAA). Additional IL2 was added every 3–4 days.
After 2 weeks cells were pooled and analyzed, cryopre-
served, or restimulated again with 1 lg/mL PHA, IL-2
and allogeneic irradiated PBMC. We know from our pre-
vious experience that this expansion protocol preserves
the TCR repertoire.24
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Generation of TCC
T-cell clones (TCCs) from CSF-infiltrating T cells sorted
after staining with specific TCR Vb-families, were estab-
lished as previously described23,24 by seeding in 96-well
U-bottom microtiter plates 0.3 T cells/well with 2 9 105
nonautologous, irradiated PBMC, 1 lg/mL of PHA-L
(Sigma) and IL-2 at the same medium used to expand
CSF cells. Additional IL-2 was added every 3–4 days and
after 2 weeks cells were pooled and analyzed, cryopre-
served, or restimulated. We know from our previous
experience that this expansion protocol does not influence
the functional phenotype since TCCs releasing different
type of cytokines have been generated.23,24
T-cell stimulation
For the analysis of cytokine release, expression of tran-
scription factors and microarrays, 1 9 106 T cells (PHA-
expanded CSF cells, peripheral memory CD4+ and CD8+
T cells and TCCs) were stimulated with 1 lg/mL of sur-
face-coated anti-CD3 (OKT3) and 107 mol/L phorbol
12-myristate 13-acetate (PMA, Sigma) for 24 h. For
degranulation and cytotoxic potential, 1 9 105 T cells
were stimulated with 1 or 10 lg/mL of surface-coated
anti-CD3 (OKT3; Ortho Biotech Products, Raritan, NJ)
and 0.5 lg/mL of soluble anti-CD28 (Biolegend) for
30 min, 1 h, 2 h, 3 h and 4 h in X-VIVO medium.
B-cell help assay
1 9 105 T cells (TCCs)/well were irradiated and then
activated with coated anti-CD3 and PMA and co-cultured
with 1 9 105 sorted autologous B cells for 7 days. As
negative control B cells were cultured alone and as posi-
tive control exogenous IL-2 (50 U/mL) and IL-4 (1 ng/
mL) were added to the cultures.
RNA extraction and retrotranscription
RNA extraction, including a DNAse treatment step, was
performed with RNeasy Micro (Qiagen, Hilden, Ger-
many) following the manufacturer’s instructions. RNA
integrity was assessed by capillary electrophoresis (Bioana-
lyzer, Agilent Technologies Inc., Santa Clara, CA). RNA
was reverse transcribed using RevertAid H minus first
strand cDNA synthesis kit (Thermo Scientific Fermentas,
Vilnius, Lithuania).
Library preparation and RNA sequencing
Library preparation for RNA-Seq was performed using
the TruSeq Stranded Total RNA with Ribo-Zero Gold
removing both cytoplasmic and mitochondrial rRNA
(Illumina, Cat. No. RS-122-2201, San Diego, CA, USA).
About 200 ng of total RNA was used as start material.
Accurate quantitation of cDNA libraries was performed
by using the QuantiFluorTM dsDNA System (Promega,
Madison, WI, USA). The size range of final cDNA
libraries was determined applying the DNA 1000 chip on
the Bioanalyzer 2100 from Agilent (280 bp). cDNA
libraries were amplified and sequenced by using the cBot
and HiSeq2000 from Illumina (SR; 1 9 50 bp; 5–6 GB
ca. 30–35 million reads per sample).25 Sequence images
were transformed with Illumina software BaseCaller to bcl
files, which were demultiplexed to fastq files with CASA-
VA v1.8.2. Quality check was done via fastqc (v. 0.10.0,
Babraham Bioinformatics http://www.bioinformatics.bab-
raham.ac.uk/). The Alignment was performed using Bow-
tie2 v2.1.0 to the h19 human reference genome. Data
were conversed and sorted by samtools 0.1.19 and reads
per gene were counted via htseq version 0.5.4.p3. Data
analysis was performed using R/Bioconductor (3.0.2/2.12)
loading DESeq, gplots and goseq packages.26 Candidate
genes were filtered to a minimum of 2 9 fold change and
FDR-corrected P < 0.05. For functional analysis gene
ontology enrichment was tested accounting for gene
length via R-package goseq http://www.bioconductor.org.
The data discussed in this paper are generated in compli-
ance with the MIAME guidelines and have been deposited
in NCBI’s Gene Expression Omnibus and are accessible
through GEO Series accession number GSE60943.
TCR Vbeta sequencing
High throughput sequencing (HTS) for Vb TCR was per-
formed on brain lesions and sorted peripheral memory
CD4+ and CD8+ T-cell subpopulations at Adaptive Bio-
technologies (Seattle, WA) using the immunoSEQ plat-
form.27
TCR variable beta (TCRBV) chain expressed by indi-
vidual TCCs was assessed as previously reported.28 Prim-
ers were obtained from Biomers (Ulm, Germany). PCR
amplification was performed in a 25 lL reaction volume
containing Pfu polymerase Buffer, 200 mmol/L deoxynu-
cleotide triphosphate, 0.5 lmol/L C3 primer, 0.5 U Pfu
DNA Polymerase (all reagents were provided by Thermo
Fisher Scientific, Reinach, Switzerland), 0.5 lmol/L for-
ward primer, and 100 ng cDNA. The cycling conditions
were as follows: initial denaturation for 4 min at 95°C
and 35 cycles of 95°C for 30 sec, primer annealing at
60°C for 20 sec, and primer extension at 72°C for 60 sec,
terminated by a final extension at 72°C for 10 min. The
PCR product was validated by electrophoresis in a 2%
agarose gel. Nucleotide sequencing of PCR products was
performed at Microsynth (Balgach, Switzerland) with
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30 pmol of reverse C1 primer. TCR gene designations are
in accord with ImMunoGeneTics (IMGT) nomenclature.
TCR gene designations are in accordance with IMGT
nomenclature (ImMunoGeneTics, www.IMGT.org). A
correspondence between IMGT nomenclature and TCR
antibodies used in this study is available in Table S1.
Quantitative RT-PCR for transcription factors
For gene expression analysis of T-cell subset-specific line-
age transcription factors, cDNAs were subjected to qPCR
with SYBR green (Applied Biosystems, Warrington, U.K.),
and expression was quantified in stimulated and unstimu-
lated TCCs by 2ddCt method29 using 18S rRNA as
endogenous control and CD4+ and CD8+ na€ıve cells as a
calibrator sample for CD4+ and CD8+ TCCs, respectively.
Flow cytometry
Degranulation and cytotoxicity potential
TCCs were stimulated with surface-coated anti-CD3 and
soluble anti-CD28 (see above) in the presence of anti-
CD107a antibody (APC, BD) and monensin (GolgiSTOP,
BD) and incubated for 30 min, 1 h, 2 h, 3 h and 4 h. At
each time-point, TCCs were harvested, washed, and ana-
lyzed for CD107a expression by flow cytometry in an
LSRFortessa cytometer (BD). Flow cytometry data were
analyzed using FACSDiva (BD) and FlowJO (TreeStar
Inc., Ashland, OR) software.
ELISA
Cytokine/chemokine release
Cytokines in the supernatant of stimulated TCCs and
expanded CSF cells and also in CSF and serum samples
were measured using the following ELISA kits: Multi-Ana-
lyte ELISArray kit for human Th1/Th2/Th17 cytokines
(Qiagen), Cytokine human 25-plex panel (Life technolo-
gies, Camarillo, CA), IL-4 (DuoSet R&D, Minneapolis,
MN), IL-5 (ELISA MAX Standard set, BioLegend, San
Diego, CA), IFN-c (ELISA MAX Standard set, BioLegend),
IL-13 (Human IL13 ELISA development kit; Mabtech
Nacka Strand, Sweden), and CXCL13 (DuoSet R&D)
according to the manufactures instructions. When indi-
cated, CSF and serum were concentrated using an Amicon
Ultra-0.5 mL centrifugal filter (Millipore, Billerica, MA).
Other inflammatory markers
CIC C1q was also quantified in CSF using the follow-
ing ELISA kit: CIC C1q (GenWay Biotech, Inc. San
Diego, CA).
Secretion of immunoglobulin subclasses
IgG1, IgG2, IgG3, and IgG4 were quantified in superna-
tants of B cells co-cultured with TCCs using the Human
IgG subclass profile ELISA kit (Life Technologies, Cama-
rillo, CA) and following the manufacturer’s instructions.
Analysis of proliferative responses
B-cell proliferation was measured by 3H-thymidine (Hart-
mann Analytic, Braunschweig, Germany) incorporation in
a scintillation counter (Wallac 1450; PerkinElmer, Rod-
gau-J€urgesheim, Germany). The stimulatory index (SI)
was calculated as follows: SI = mean cpm (B cells co-cul-
tured with TCC)/mean cpm (B cells alone).
Microarrays
Microarrays were done using the “Low RNA Input linear
Amplification Kit Plus, One Color” protocol (Cat. No.:
5188-5339, 2007; Agilent Technologies, Inc., Santa Clara,
CA) and the Agilent RNA Spike-In Kit for One color
(Agilent Technologies, Inc. 2007; Cat. No.: 5188-5282)
following the manufacturer’s standard protocol. Global
gene expression analysis was applied using the Agilent
SurePrint G3 Human GE v2 8 9 60K Kit, P/N G4851B
(Agilent Microarray Design ID 039494). About 200 ng of
total RNA was used as a starting material to prepare
cDNA. cDNA synthesis and in vitro transcription (IVT)
were performed according to the manufacturer’s recom-
mendation. Quantity and efficiency of the labeled ampli-
fied cRNA were determined using the NanoDrop ND-
1000 UV-VIS Spectrophotometer version 3.2.1. The
hybridizations were performed for 17 h at 10 rpm and
65°C in the hybridization oven (Agilent). Washing and
staining of the arrays were done according to the manu-
facturer’s recommendation. Cy3 intensities were detected
by one-color scanning using an Agilent DNA microarray
scanner (G2505B) at 5 micron resolution. Scanned image
files were visually inspected for artifacts and then ana-
lyzed. Intensity data were extracted using Agilent’s Fea-
ture Extraction (FE) software (version 11.5.1.1) including
a quality control based on internal controls using Agi-
lent’s protocol GE1_107_Sep09. All chips passed the qual-
ity control and were analyzed using the Limma package30
of Bioconductor.31
Results
Demyelinating pattern II clinical case
Autopsy brain tissue from a MS patient (Fig. S1 and
Patients and Methods) was examined. Three demyelinated
ª 2015 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. 879
R. Planas et al. T Cells in Demyelinating Lesions Pattern II
lesions were identified and immunohistochemically ana-
lyzed (Fig. 1). On the basis of myelin degradation prod-
ucts present within the macrophages/microglia, lesions
were classified as follows: lesion I (L-I): center inactive
and edge late active (Fig. 1A–C); lesion II (L-II): inactive
(Fig. 1E and F); and lesion III (L-III): center late active
and edge early active (Fig. 1H–J). L-I and L-III showed a
macrophage rim at the lesion edge (Fig. 1D and K), but
not L-II (Fig. 1G). Antibody-producing plasma cells were
present in all three lesions (Fig. 1L–N), and deposition of
activated complement C9neo antigen was observed in L-
III at sites of early active myelin degradation (Fig. 1O)
consistent with demyelinating pattern II.4 CD4+ and
CD8+ infiltrating T lymphocytes were found in the three
lesions (Fig. S2). Table 1A summarizes the immune cell
infiltrates in these lesions.
Transcriptome analysis of the three lesions by RNA
sequencing demonstrated the presence of mRNA tran-
scripts for genes specific of activated macrophages, T and
B cells as well as genes coding for immunoglobulins,
complement proteins and some pattern II-associated pro-
teins such as CCR1, a chemokine receptor expressed by
macrophages in pattern II MS lesions32,33 and IL-18-bind-
ing protein, an inhibitor of the early Th1 cytokine
response34 (Table 1B). Only genes with reads per kilobase
of exon model per million mapped reads (RPKM) values
higher than 1 were analyzed. RPKM values for oligoden-
drocyte, astrocyte, and neuron-specific genes are shown as
quality control of the samples and also as reference for
genes expressed at high (myelin proteolipid protein 1
[PLP1], MBP, glial fibrillary acidic protein [GFAP] and
neurofilament [NEFL]) or medium (MAG, myelin-associ-
ated oligodendrocyte basic protein [MOBP] and oligo-
dendrocyte myelin glycoprotein [OMG]) level.
Identification and cloning of disease-
relevant CD4+ and CD8+ T Cells
Using a next-generation TCR sequencing approach,27 we
sequenced the TCRBV chain expressed by T cells infiltrat-
ing the active brain L-III. A total of 312 unique produc-
tive sequences were identified. The 50 most frequent
T-cell clones (TCCs) are summarized in Table 2, and a
complete list is available in Table S2. In order to discrimi-
nate between CD4+ and CD8+ TCCs, we also sequenced
the TCRBV chain expressed by 2 9 105 purified autolo-
gous peripheral memory CD4+ and 2 9 105 CD8+ T cells.
23,000 unique productive sequences were identified in the
CD4+ and 12,174 in the CD8+ memory T-cell pool. L-III-
infiltrating TCCs that are present in the memory CD4+
T-cell pool are shown in red (34%) in Table 2, while
TCCs present in the memory CD8+ T-cell pool are shown
in blue (66%).
Using monoclonal antibodies specific for the TCRBV
families expressed by the 50 most frequent TCCs in L-III
we sorted previously PHA-expanded CSF-infiltrating T
cells from the same patient, cloned them by limiting dilu-
tion and sequenced the CDR3 region (Fig. S3). Using this
approach we have generated 32 TCCs, of which 16 were
present in brain L-III (Table S3). Thirteen of these 16
TCCs were among the 50 most frequent in this lesion,
while three of them ranked lower regarding frequency.
Nine of these TCCs were CD8+, six CD4+, and one could
not be stained because of low growth (Table 2).
We searched for CDR3 sequences containing silent
nucleotide exchanges as indicator of antigen-driven stim-
ulation. Although we identified CDR3 sequences with
silent mutations in the most expanded TCCs (Table S4),
the low frequency of these indicates that they are likely
sequencing errors. However, we found that the most fre-
quent TCCs shared identical CDR3 sequences with other
TCCs that are present in the same lesion and express dif-
ferent TCRBV chains (Table 3). Interestingly, this phe-
nomenon was restricted to some TCRBV chains with
high amino acid sequence homology in the CDR1 and
CDR2 regions (Table S5).
A search using BLASTP program of the nonredundant
protein database (http://blast.ncbi.nlm.nih.gov) indicated
that none of the 312 TCR sequences found in L-III
matched any sequence in the database.
Next, we also sequenced the TCRBV chains of T cells
infiltrating the two less active lesions, L-I and L-II. We
identified 99 unique productive sequences in L-I and 57
in L-II. The 25 most frequent TCCs in both lesions are
Figure 1. Pathological features of demyelinating lesions (pattern II patient). Brain picture showing the localization of the three demyelinating
lesions. Lesion I, demyelinating lesion (A) with inactive demyelinated lesion center (absence of myelin degradation products within macrophages)
and late active demyelinating lesion edge (B and C). Late active demyelinating lesion areas are characterized by the presence of major myelin
proteins such as MBP and PLP within macrophages (arrows in C). The lesion shows a macrophage rim at the border (D). Lesion II, inactive
demyelinated lesion (E and F) without macrophage rim at the border (G). Lesion III, demyelinating lesion (H) with late active demyelinating lesion
center and early active demyelinating lesion edge (I and J). Early active demyelinating lesion areas are characterized by the presence of minor
myelin proteins such as MOG within macrophages (arrows in J) in addition to major myelin proteins. A macrophage rim at the lesion border is
present (K). Antibody-producing plasma cells are found in lesion I (L), lesion II (M) and lesion III (N), in which also complement deposits are
present (O). Original magnifications: (A) 209. (B) 2009. (C) 4009. (D) 209. (E) 409. (F) 1009. (G) 409. (H) 209. (I) 1009. (J) 4009. (K) 209. (L)
2009. (M) 2009. (N) 2009. (O) 4009. MBP, myelin basic protein; PLP, proteolipid protein; MOG, myelin oligodendrocyte glycoprotein.
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Table 1. Characterization of brain lesions.
L no.
Demyelinating
activity
CD3+
(cells/mm2)
CD4+
(cells/mm2)
CD8+
(cells/mm2)
CD20+
(cells/mm2)
IgG+
(cells/mm2)
CD138+
(cells/mm2)
(A) Histopathological features of brain lesions
I
Lesion edge Late active 42.4 15.4 25.6 0 16.9 9.6
Lesion center Inactive 36.8 11.2 24 0 16.8 15.2
II
Lesion Inactive 22.1 4.2 20 1.8 n.a. 51.2
III
Lesion edge Early active 63.2 17.2 35.2 0 n.a. 11.2
Lesion center Late active 31.2 20.0 24.8 1.6 n.a. 26.4
Gene Description L-I1 L-II L-III
(B) RNA-seq transcriptome analysis of brain lesions
Brain
Oligodendrocytes PLP1 Proteolipid protein 1 458.31 341.43 431.91
MBP Myelin basic protein 37.20 28.97 59.21
MAG Myelin-associated glycoprotein 16.29 10.83 26.84
MOBP Myelin-associated oligodendrocyte basic protein 14.48 11.16 19.82
OMG Oligodendrocyte myelin glycoprotein 5.21 5.07 3.26
Astrocytes GFAP Glial fibrillary acidic protein 297.88 204.40 509.07
Neurons NEFL Neurofilament, light polypeptide 77.32 89.86 95.98
Immune system
Macrophages/microglia CD74 CD74 molecule, MHC, class II invariant chain 15.80 10.66 17.79
CD63 CD63 molecule 15.26 11.82 14.09
CD14 CD14 molecule 10.19 6.11 11.00
CD163 CD163 molecule 1.25 0.97 1.05
IL18BP Interleukin 18-binding protein 2.09 1.82 3.32
HLA-DRB1 MHC class II, DR beta 1 1.76 1.14 1.45
HLA-DQB1 MHC class II, DQ beta 1 1.47 0.68 1.07
HLA-DRB5 MHC class II, DR beta 5 1.46 0.80 0.86
CCR1 Chemokine (C-C motif) receptor 1 1.47 0.84 1.08
ITGAX Integrin, alpha X, CD11c (component 3 CR4) 1.31 0.66 1.56
ITGB2 Integrin beta 2, CD18 (CR3 and 4) 1.27 0.48 1.33
T cells CD2BP2 CD2 (cytoplasmic tail)-binding protein 2 15.48 12.19 17.51
IL17RA Interleukin 17 receptor A 1.44 1.10 1.81
IL10RA Interleukin 10 receptor, alpha 1.14 0.69 1.33
B cells CD22 CD22 molecule 2.02 1.51 7.21
CD81 CD81 molecule 11.62 7.82 14.26
CD37 CD37 molecule 1.36 0.58 1.51
IGKJ4 Immunoglobulin kappa joining 4 117.00 85.40 52.48
IGKV4-1 Immunoglobulin kappa variable 4-1 8.65 19.16 0.70
IGKV3-11 Immunoglobulin kappa variable 3-11 1.04 6.66 0.00
IGHV4-31 Immunoglobulin heavy variable 4-31 5.76 4.24 19.46
IGHV4-31 Immunoglobulin heavy variable 4-31 2.53 0.57 0.00
IGHV3-48 Immunoglobulin heavy variable 3-48 1.98 4.58 0.33
IGHMBP2 Immunoglobulin mu-binding protein 2 0.88 0.69 1.19
Complement C1QC Complement component 1q, C chain 12.51 6.83 12.21
C1QA Complement component 1q, A chain 9.43 4.49 9.04
C1QB Complement component 1q, B chain 7.20 4.32 7.52
C1QL3 Complement component 1q subcomponent-like 3 1.70 2.19 1.86
C1QL2 Complement component 1q subcomponent-like 2 1.68 0.98 2.87
C3 Complement component 3 5.49 3.28 7.00
CD59 CD59 molecule, complement regulatory protein 5.24 4.17 3.13
CD46 CD46 molecule, complement regulatory protein 2.66 2.60 2.32
Mononuclear IL18BP Interleukin 18-binding protein 2.09 1.82 3.32
1Values given in the table represent reads per kilobase of exon model per million mapped reads (RPKM).
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summarized in Table 4 and a complete list is available in
Table S6. Using TCRBV sequence information from the
peripheral memory CD4+ and CD8+ T-cell pools, we
identified 11 CD8+ and six CD4+ TCCs in L-I, and 12
CD8+ and only four CD4+ TCCs in L-II. In these two
lesions we did not find TCCs sharing identical CDR3
sequences as we observed in L-III. Regarding TCR over-
lap, only three TCCs were present in the three lesions but
we were unable to generate them from the CSF. Six TCCs
were shared only by L-I and L-II, eight only by L-I and
L-III, and three only by L-II and L-III (Tables 2, 4 and
S2, S6). Two TCCs generated from the CSF and present
in L-III (TCC13.1-13 and TCC21-1) were also found in
L-I although not among the 25 most frequent clones, but
ranking lower regarding frequency (Table 4). As regards
L-II, two of the TCCs generated from the CSF and pres-
ent in L-III (TCC 17-1 and TCC 17-2) were the most fre-
quent TCCs in this lesion (Table 4). In an effort to
obtain more TCCs expanded in inactive lesions, we sorted
PHA-expanded CSF-infiltrating T cells using anti-BV3
TCCs generated from the CSF are shown in bold.
CD8+ TCCs are highlighted in blue and CD4+ TCCs in red.
1CDR3 sequences shared by different TCCs are indicated with *.
2TCR gene designations are in accord with IMGT nomenclature.
3Antibodies available for the specific BV families.
Table 3. CDR3 sequences shared by different TCCs.
TCC RANK NUCLEOTIDE SEQUENCE CDR3 COUNT TCRBV TCRBD TCRBJ 
     
 1 CTGACAGTGACCAGTGCCCATCCTGAAGACAGCAGCTTCTACATC TGCAGTGCTAGTGAGGGGGTTTACGAGCAGTACTTC GGGCCG CSASEGVYEQYF 493497 20 01-01*01 02-07*01 
 28 CTGACTGTGAGCAACATGAGCCCTGAAGACAGCAGCTTCTACATC TGCAGTGCTAGTGAGGGGGTTTACGAGCAGTACTTC GGGCCG CSASEGVYEQYF 395 29-01*01 01-01*01 02-07*01 
     
 2 GAGCTGAATGTGAACGCCTTGTTGCTGGGGGACTCGGCCCTCTATCTC TGTGCCAGCAGCTCAGGTCCGGGAGAAGCTTTT GGCCCA CASSSGPGEAF 356183 05-06*01 02-01*02 02-03*01 
 18 GAGCTGAATGTGAACGCCTTGGAGCTGGACGACTCGGCCCTGTATCTC TGTGCCAGCAGCTCAGGTCCGGGAGAAGCTTTT GGCCCA CASSSGPGEAF 2070 05-04*01 02-01*02 02-03*01 
 75 ACTCTGAAGATCCAGCCCTCAGAACCCAGGGACTCAGCTGTGTACTTC TGTGCCAGCAGCTCAGGTCCGGGAGAAGCTTTT GGCCCA CASSSGPGEAF 9 12 02-01*02 02-03*01 
 114 TTCCTTCACCTACACACCCTGCAGCCAGAAGACTCGGCCCTCTATCTC TGTGCCAGCAGCTCAGGTCCGGGAGAAGCTTTT GGCCCA CASSSGPGEAF 4 04-02*01 02-01*02 02-03*01 
     
 3 AACATGAGCCCTGAAGACAGCAGCATATATCTC TGCAGCGTTGAAATTTCGAAGGGGACAGGGAACTATGGCTACACCTTC GGTTCG CSVEISKGTGNYGYTF 252110 29-01*01 01-01*01 01-02*01 
 50 AGTGCCCATCCTGAAGACAGCAGCTTCTATCTC TGCAGCGTTGAAATTTCGAAGGGGACAGGGAACTATGGCTACACCTTC GGTTCG CSVEISKGTGNYGYTF 29 20 01-01*01 01-02*01 
 57 GCCTTGTTGCTGGGGGACTCGGCCCTCTATCTC TGCAGCGTTGAAATTTCGAAGGGGACAGGGAACTATGGCTACACCTTC GGTTCG CSVEISKGTGNYGYTF 20 05-06*01 01-01*01 01-02*01 
     
 4 AGCAACATGAGCCCTGAAGACAGCAGCATATATCTC TGCAGCGTTTTCCAGGACAGGGGAAGCAGCGGGGAGCTGTTTTTT GGAGAA CSVFQDRGSSGELFF 169488 29-01*01 01-01*01 02-02*01 
 75 ACCAGTGCCCATCCTGAAGACAGCAGCTTATATCTC TGCAGCGTTTTCCAGGACAGGGGAAGCAGCGGGGAGCTGTTTTTT GGAGAA CSVFQDRGSSGELFF 8 20 01-01*01 02-02*01 
     
 5 AGTGCCCATCCTGAAGACAGCAGCTTCTACATC TGCAGTGCTCAGGGACTAGCGGGGGGGCACGTAGATGAGCAGTTCTTC GGGCCA CSAQGLAGGHVDEQFF 111505 20 02-01*01 02-01*01 
 49 AACATGAGCCCTGAAGACAGCAGCATATATCTC TGCAGTGCTCAGGGACTAGCGGGGGGGCACGTAGATGAGCAGTTCTTC GGGCCA CSAQGLAGGHVDEQFF 31 29-01*01 02-01*01 02-01*01 
     
 6 CAGCCCTCAGAACCCGGGGACTCAGCTGTGTACTTC TGTGCCAGCAGTTTATCTGGGACAGGGGTCTACGAGCAGTACTTC GGGCCG CASSLSGTGVYEQYF 81616 12 01-01*01 02-07*01 
 60 GAGTCGGCTGCTCCCTCCCAGACATCTGTGTACTTC TGTGCCAGCAGTTTATCTGGGACAGGGGTCTACGAGCAGTACTTC GGGCCG CASSLSGTGVYEQYF 17 06-01*01 01-01*01 02-07*01 
 73 AACGCCTTGGAGCTGGACGACTCGGCCCTGTATCTC TGTGCCAGCAGTTTATCTGGGACAGGGGTCTACGAGCAGTACTTC GGGCCG CASSLSGTGVYEQYF 9 05-04*01 01-01*01 02-07*01 
 81 CGGTCCACAAAGCTGGAGGACTCAGCCATGTACTTC TGTGCCAGCAGTTTATCTGGGACAGGGGTCTACGAGCAGTACTTC GGGCCG CASSLSGTGVYEQYF 7 02-01*01 01-01*01 02-07*01 
 84 CTGTCGGCTGCTCCCTCCCAGACATCTGTGTACTTC TGTGCCAGCAGTTTATCTGGGACAGGGGTCTACGAGCAGTACTTC GGGCCG CASSLSGTGVYEQYF 6 06-05*01 01-01*01 02-07*01 
     
 7 ATCCGGTCCACAAAGCTGGAGGACTCAGCCATGTACTTC TGTGCCAGCAGTGAGGGGGGGTAGAATTCACCCCTCCACTTT GGGAAC CASSEGGYNSPLHF 25295 02-01*01 02-01*01 01-06*01 
 54 ATCCAGCCCTCAGAACCCGGGGACTCAGCTGTGTACTTC TGTGCCAGCAGTGAGGGGGGGTAGAATTCACCCCTCCACTTT GGGAAC CASSEGGYNSPLHF 25 12 02-01*01 01-06*01 
     
 8 CTGAATGTGAACGCCTTGGAGCTGGACGACTCGGCCCTGTATCTC TGTGCCAGCAGCTTAGGACAGGGCGAGCAGTACTTC GGGCCG CASSLGQGEQYF 25076 05-04*01 01-01*01 02-07*01 
 74 CTGAAGATCCAGCCCTCAGAACCCGGGGACTCAGCTGTGTACTTC TGTGCCAGCAGCTTAGGACAGGGCGAGCAGTACTTC GGGCCG CASSLGQGEQYF 9 12 01-01*01 02-07*01 
     
 9 GTGAACGCCTTGTTGCTGGGGGACTCGGCCCTCTATCTC TGTGCCAGCAGCTTGCAGGGGTGGGCCACTGAAGCTTTCTTT GGACAA CASSLQGWATEAFF 24987 05-06*01 01-01*01 01-01*01 
 33 GTGAACGCCTTGGAGCTGGACGACTCGGCCCTGTATCTC TGTGCCAGCAGCTTGCAGGGGTGGGCCACTGAAGCTTTCTTT GGACAA CASSLQGWATEAFF 143 05-04*01 01-01*01 01-01*01 
     
 10 AATGTGAACGCCTTGTTGCTGGGGGACTCGGCCCTCTATCTC TGTGCCAGCAGCTTGTACAGGGGAGGTACGCAGTATTTT GGCCCA CASSLYRGGTQYF 13291 05-06*01 01-01*01 02-03*01 
 39 AATGTGAACGCCTTGGAGCTGGACGACTCGGCCCTGTATCTC TGTGCCAGCAGCTTGTACAGGGGAGGTACGCAGTATTTT GGCCCA CASSLYRGGTQYF 94 05-04*01 01-01*01 02-03*01 
     
 11 GTGAACGCCTTGTTGCTGGGGGACTCGGCCCTCTATCTC TGTGCCAGCAGCTTGGGCAGGGTTTCATGGGGCTACACCTTC GGTTCG CASSLGRVSWGYTF 8219 05-06*01 01-01*01 01-02*01 
 47 GTGAACGCCTTGGAGCTGGACGACTCGGCCCTGTATCTC TGTGCCAGCAGCTTGGGCAGGGTTTCATGGGGCTACACCTTC GGTTCG CASSLGRVSWGYTF 83 05-04*01 01-01*01 01-02*01 
     
13.1-13 12 CTGGAGTCGGCTGCTCCCTCCCAGACATCTGTGTACTTC TGTGCCAGCAGTGAGTTAGCGGGGTTCTACGAGCAGTACTTC GGGCCG CASSELAGFYEQYF 6936 06-01*01 02-01*01 02-07*01 
 59 ATCCAGCCCTCAGAACCCGGGGACTCAGCTGTGTACTTC TGTGCCAGCAGTGAGTTAGCGGGGTTCTACGAGCAGTACTTC GGGCCG CASSELAGFYEQYF 18 12 02-01*01 02-07*01 
     
 13 CCCTCAGAACCCAGGGACTCAGCTGTGTACTTC TGTGCCAGCAGCTTGGTACTTCCCACTAGCACAGATACGCAGTATTTT GGCCCA CASSLVLPTSTDTQYF 6748 12 02-01 02-03*01 
 112 GCCTTGTTGCTGGGGGACTCGGCCCTCTATCTC TGTGCCAGCAGCTTGGTACTTCCCACTAGCACAGATACGCAGTATTTT GGCCCA CASSLVLPTSTDTQYF 4 05-06*01 02-01 02-03*01 
     
 14 CAGCCCTCAGAACCCAGGGACTCAGCTGTGTACTTC TGTGCCAGCACCCCCTCGGGAGTAGGCACAGATACGCAGTATTTT GGCCCA CASTPSGVGTDTQYF 5836 12 02-01*02 02-03*01 
     
13.1-12 15 TCGGCTGCTCCCTCCCAGACATCTGTGTACTTC TGTGCCAGCAGTTACTCCTTCGAGCCAGCACAAGAGACCCAGTACTTC GGGCCA CASSYSFEPAQETQYF 5200 06-05*01 - 02-05*01 
 94 CCCTCAGAACCCGGGGACTCAGCTGTGTACTTC TGTGCCAGCAGTTACTCCTTCGAGCCAGCACAAGAGACCCAGTACTTC GGGCCA CASSYSFEPAQETQYF 5 12 - 02-05*01 
     
8.1-35 16 AAGATCCAGCCCTCAGAACCCAGGGACTCAGCTGTGTACTTC TGTGCCAGCAGTCCCAGCATGGGGGATGGCTACACCTTC GGTTCG CASSPSMGDGYTF 4790 12 - 01-02*01 
 111 AAGATCCGGTCCACAAAGCTGGAGGACTCAGCCATGTACTTC TGTGCCAGCAGTCCCAGCATGGGGGATGGCTACACCTTC GGTTCG CASSPSMGDGYTF 4 02-01*01 - 01-02*01 
     
 17 CCCTCAGAACCCAGGGACTCAGCTGTGTACTTC TGTGCCAGCAGCTTGGTACTTCCCACTAGCACAGATAGGCAGTATTTT GGCCCA CASSLVLPTSTDRQYF 2394 12 02-01 02-03*01 
 113 GCCTTGTTGCTGGGGGACTCGGCCCTCTATCTC TGTGCCAGCAGCTTGGTACTTCCCACTAGCACAGATAGGCAGTATTTT GGCCCA CASSLVLPTSTDRQYF 4 05-06*01 02-01 02-03*01 
     
Nucleotide sequence of the most frequent T cell clones are shown in bold. Different nucleotide between sequences are shown in red and underlined. -, unresolved. 
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and -BV12 antibodies, then cloned them by limiting dilu-
tion and sequenced the CDR3 region. We generated nine
new TCCs but unfortunately none of them matched
TCCs present in these lesions (Table S3).
Functional phenotype of brain-infiltrating
CD8+ and CD4+ T-cell clones in
demyelinating pattern II lesions
Next, we examined the functional phenotype of four
brain-infiltrating CD8+ TCCs by analyzing their cytokine
profile after stimulation using a semi-quantitative ELIS-
Array (Fig. 2A). TCC17-2 displayed a classic Tc1 pheno-
type, releasing mainly Th1 cytokines. TCC22-1 released
in addition to Th1 also Th2 cytokines showing a Tc0
phenotype. Interestingly, two TCCs (TCC4-1 and TCC7-
5) displayed a Tc2 phenotype, releasing mainly Th2
cytokines. In order to confirm the existence of these dif-
ferent CD8 functional subsets, two of these TCCs,
TCC17-2 (Tc1, present in L-III and L-II) and TCC4-1
(Tc2, ranking in position 24 regarding frequency in
L-III) were characterized further. Quantification of cyto-
kine release by a 25-plex Luminex panel confirmed the
secretion of Th1 cytokines by TCC17-2 and Th2 cyto-
kines by TCC4-1. In addition, both TCCs released
similar amounts of IL-2, GM-CSF, MIP-1a, MIP-1b, and
IL-8 (Fig. 2B). TCC4-1 expressed the Th2 transcription
factor GATA-3 after stimulation while none of the tested
transcription factors was clearly upregulated in TCC17-2
(Fig. 2C). Following stimulation with anti-CD3, both
CD8+ TCCs increased the expression of CD107a, a mar-
ker of degranulation and cytotoxic activity, although
TCC4-1 expressed lower levels than TCC17-2 indicating
lower cytotoxic potential (Fig. 2D). Using microarrays,
gene expression patterns of both TCCs after stimulation
were compared. Figure 3A summarizes the differential
expression in both TCCs of Tc1- and Tc2-associated
genes. Tc2-associated genes were expressed at higher lev-
els by TCC4-1, while Tc1-associated genes were upregu-
lated in TCC17-2.
We also examined the functional phenotype of the six
brain-infiltrating CD4+ TCCs (Fig. 2A). Three TCCs
(TCC8.1-2, TCC21-1, and TCC17-1) displayed a Th2
phenotype releasing mainly Th2 cytokines, two TCCs
(TCC5.2-1 and TCC8.1-101) had a Th1/2 functional phe-
notype and only TCC8.1-35 released mainly Th1 cyto-
TCCs generated from the CSF are shown in bold.
CD8+ TCCs are highlighted in blue and CD4+ TCCs in red.
1TCR gene designations are in accord with IMGT nomenclature.
2Antibodies available for the specific BV families.
Figure 2. Functional characterization of brain-infiltrating T cells in demyelinating lesions pattern II. (A) Cytokine release by CD8+ (blue) and CD4+
(red) CSF-derived brain-infiltrating TCCs after stimulation with anti-CD3 and PMA for 24 h using a semi-quantitative multi-analyte ELISArray. Full
color indicates OD > 3, medium color indicates 2 > OD > 3, light color 1 > OD > 2 and white OD < 1. (B) Quantification of cytokine and
chemokine release by two selected CD8+ (blue) and two CD4+ (red) TCCs using 25-plex Luminex panel. (C) RT-PCR analysis for transcription
factors t-bet, Gata-3, RORct, FOXp3, Eomes and BCL6 in two CD8+ (blue) and two CD4+ (red) brain-infiltrating TCCs unstimulated () or
stimulated with anti-CD3 and PMA for 24 h (+). Values are relative expression compared to purified naive CD8+ or CD4+ T cells respectively. (D)
Time course expression of CD107a after stimulation with 1 or 10 lg/mL of anti-CD3 on two CD8+ brain-infiltrating TCCs. Histograms show the
percentage of CD107a+ T cells. (E) Proliferative response measured as thymidine incorporation (counts per minute [cpm]) of B cells cultured alone
or co-cultured with irradiated TCCs (two CD4+ [red] and one CD8+ [blue] are shown) in the absence () of presence (+) of IL-2 and IL-4.
Irradiated TCCs cultured alone were included as additional control. Histograms show cpm. (F) Production of IgG subclasses by B cells cultured
alone or co-cultured with irradiated TCCs (two CD4+ [red] and one CD8+ [blue] TCC). All histograms show the mean + SEM. All results represent
three independent experiments. CSF, cerebrospinal fluid; OD, optic density.
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kines. In order to discard an effect of the expansion pro-
tocol on T-helper phenotypes, two MBP-specific CD4+
TCCs generated from PBMCs of a MS patient35,36 have
been expanded using identical approach and reagents and
have been analyzed as controls. As shown in Figure 2A,
these TCCs did not express Th2 cytokines. In order to
confirm the Th2 phenotype of brain-infiltrating CD4+ T
cells in demyelinating lesions pattern II, two of the Th2
TCCs, TCC21.1 (present in L-III and L-I) and TCC17-1
(present in L-III and L-II) were characterized further.
Quantification of cytokine release by the 25-plex Luminex
panel confirmed the secretion of Th2 cytokines by both
TCCs as well as the release of similar amounts of MIP-1a,
MIP-1b, and IL-8. TCC21-1 released higher amounts of
IL-10 and GM-CSF than TCC17-1 (Fig. 2B). Both TCCs
expressed the Th2 transcription factor GATA-3 after stim-
ulation but not the transcription factor BCL6, which is
characteristic for follicular helper T cells (Fig. 2C), and
neither the B-cell chemoattractant CXCL13 (data not
shown). Using microarrays, we compared gene expression
profiles after stimulation in both TCCs with pooled autol-
ogous peripheral memory CD4+ T cells. Th2-associated
genes were upregulated in these two TCCs while Th1,
Th17 and Treg-associated genes were downregulated
(Fig. 3B).
Effects of Th2 and Tc2 T-cell clones on B-cell
proliferation and antibody production
Next, we explored whether brain-infiltrating Th2 and Tc2
TCCs were able to provide help for B-cell proliferation
and antibody production. Autologous B cells were cul-
tured alone or co-cultured for 7 days with irradiated
TCC21.1 (Th2) or TCC4-1 (Tc2) supplemented or not
with IL-2 and IL-4. Proliferation was measured by thymi-
dine incorporation and release of the four subclasses of
IgG was measured by ELISA. An irradiated Th1 TCC spe-
cific for MBP (TCC TL3A6) served as control. No prolif-
eration was detected when B cells or irradiated T cells
were cultured alone. B cells co-cultured with irradiated
TCC21-1 and TCC4-1 proliferated at similar levels, and
proliferation was not enhanced by the addition of IL-2
and IL-4. Irradiated TCC TL3A6 was not able to help B
cells to proliferate, and B cells only proliferated when IL-
2 and IL-4 were added to the co-cultures (Fig. 2E). Only
TCC21-1 was able to provide B cell help for antibody
production (Fig. 2F). Although the main subclass released
was IgG1, TCC21-1 helped B cells to produce all IgG sub-
types. The low expression of CD40L by TCC4-1 com-
pared with TCC21-1 (Fig. S4) might underlie the inability
of this TCC to provide B cell help for antibody produc-
tion.
CSF-infiltrating Th2 cells as potential
biomarker for pattern II demyelinating
lesions
In order to assess whether a bias to Th2 cytokines is a
feature of CSF-infiltrating T cells in this MS patient with
pattern II demyelinating brain lesions, we compared the
functional phenotype of PHA-expanded infiltrating CSF T
cells from this patient with cells from another patient
with pattern III demyelinating lesions (see Patients and
Methods). CSF T cells from the pattern II patient released
higher amounts of Th2 cytokines and lower quantities of
Th1 cytokines than CSF cells from the pattern III patient
(Fig. 4A). This bias to Th2 cytokines was restricted to T
cells from the CSF, since circulating memory CD4+,
CD8+, and total PBMCs mainly released Th1 cytokines
(Fig. 4A). No cytokines were detectable in CSF or serum
even after concentration. The Th2 bias of CSF-infiltrating
T cells in the pattern II patient was confirmed using
ELISA (Fig. 4B). CSF from the pattern II patient also
contained higher levels of several biomarkers associated
with this pattern such as the B-cell chemoattractant
CXCL13, circulating C1q fixing immune complexes (CiC
C1q) and intrathecal IgG antibodies (Fig. 4C).
Discussion
Heterogeneity is a hallmark of all complex genetic disor-
ders including MS. Understanding its cellular and molec-
ular basis is expected to improve the diagnosis, prognosis,
and treatment decisions toward personalized medicine. As
an important step in this direction, the description of
four immunopathological patterns of MS4 can be consid-
ered a milestone in MS research. These patterns have thus
far not found universal acceptance, most likely because it
Figure 3. Gene expression profile of brain-infiltrating CD4+ and CD8+ TCCs. (A) TCC 4.1 (Tc2) and TCC 17.2. (Tc1) were stimulated and their
expression profile analyzed by microarrays. Histogram values show differential expression of Tc1- and Tc2-associated genes measured as
microarray fluorescence intensity. (B) TCC 17-1, TCC 21-1 and circulating memory CD4+ T cells were stimulated and their expression profile
analyzed by microarrays. Heat map shows Th1-, Th2-, Th17- and Treg-associated genes differentially expressed in TCC 17-1 and TCC 21-1
compared with circulating memory CD4+ T cells. I and II are two independent expansions and stimulations of the same TCC. Blue are genes
upregulated and yellow downregulated compared with expression in circulating memory CD4+ T cells. Values represent log2FC TCC – circulating
memory CD4+ T cells.
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has been difficult to obtain functional evidence. The
expression of distinct chemokine receptors in different
patterns,33 a more favorable response to therapeutic
plasma exchange6 and a unique serum antibody signature
in patients with demyelinating pattern II37 give indirect
support, however, direct functional evidence is still miss-
ing. Here, we demonstrate that CD4+ and CD8+ T cells,
which release Th2 cytokines and are capable to provide
B-cell help, dominate the T-cell infiltrate in demyelinating
pattern II MS brain lesions. These data might close an
important gap by linking a certain functional phenotype
of T cells with antibody and complement deposition in
pattern II lesions.
Immunopathological characterization of brain tissue
from our clinical case allowed us to identify deposition
of activated complement protein at sites of active myelin
destruction in active L-III indicating demyelinating pat-
tern II.4 Consistent with this pattern, antibody-produc-
ing plasma cells were present in this lesion, but also in
the other two less active lesions (L-I and II). In agree-
ment with previous reports,38,39 we found an inverse
correlation between frequency of antibody-producing
plasma cells and lesion activity. Although from a clinical
point of view, this patient might be seen as an atypical
MS patient, histopathological analysis of brain active
lesions showed clear features consistent with pattern II
demyelination. Furthermore, RNA-sequencing transcrip-
tome analysis of the three lesions provided additional
evidence supporting pattern II demyelination. Interest-
ingly, while the transcription of brain-derived and most
immune-related genes was comparable between the three
brain lesions, the expression of genes corresponding to
the variable regions of antibodies varied markedly, indi-
cating clonal expansion of different antibody-producing
B cells.
Immunohistological characterization and TCR sequenc-
ing in the three lesions confirmed greater abundance16,17
and clonal expansion of CD8+ T cells,18–20 but in addition
demonstrated for the first time clonal expansion of CD4+
T cells. Only three identical TCCs were detected in the
three brain lesions. The different activity level of the three
lesions and a potential sampling bias, since we can only
analyze a fraction of the infiltrate, most likely underlie
this TCR heterogeneity. L-III, the most active lesion,
showed the highest density of infiltrating T cells and also
the highest number of different TCCs, followed by L-I
and finally the inactive L-II, indicating a correlation
between the inflammatory activity or stage of the lesion
and the extent of the T-cell infiltrate. Accordingly, the
number of shared TCCs was higher for L-III and L-I than
for L-III and L-II. Different from other studies,20 we were
not able to find silent mutations in the CDR3 of the most
expanded infiltrating TCCs that might suggest antigen-
driven stimulation. However, we found that the most
expanded TCCs shared identical CDR3s with other TCCs
expressing different TCRBV chains with similar CDR1
and CDR2 regions. Since CDR3 regions primarily contact
the antigenic peptide and CDR1 and CDR2 portions of
the HLA molecule, these TCCs might recognize the same
HLA/antigen complex.40
The sequencing data of the TCR repertoire from L-III
guided us to focus on specific TCCs. Regarding isolation
of relevant TCCs, we faced, however, still important limi-
tations: (1) that the CSF was not an ideal surrogate for
Figure 4. Functional characterization of CSF-infiltrating T cells in demyelination pattern II. (A) Cytokine measurement using a semi-quantitative
multi-analyte ELISArray in concentrated serum and CSF fluid, and in supernatants of PHA-expanded CSF-infiltrating T cells, memory circulating
CD4+ and CD8+ T cells and total PBMCs from a demyelinating pattern II and pattern III patient respectively after stimulation with anti-CD3 and
PMA for 24 h. Black indicates OD > 3, dark gray 2 > OD > 3, light gray 1 > OD > 2 and white OD < 1. (B) Quantification of cytokine and
chemokine release by PHA-expanded CSF-infiltrating T cells from demyelinating pattern II (black) and pattern III (white) patients by ELISA. (C)
Quantification of CXCL13, CiC C1q and IgG antibodies in the CSF fluid from a demyelinating pattern II (black) and pattern III (white) patients.
CSF, cerebrospinal fluid; PBMCs, peripheral blood mononuclear cells; OD, optic density.
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the central nervous system (CNS), since the T-cell infil-
trate in the two compartments is probably never identical,
(2) that our methodological approach allows only the iso-
lation of TCCs expressing BV families, for which antibod-
ies are available, and finally (3) that the most frequent
TCCs, if present in the CSF, were exhausted and difficult
to expand. We were not able to isolate from the CSF the
most frequent TCCs in L-III, although BV antibodies
were available. This suggests that these TCCs were either
confined to the CNS parenchyma at the time of death of
the patient and/or too exhausted for further in vitro
expansion. Nevertheless, we succeeded in isolating thir-
teen of the 50 most frequent TCCs in L-III, and their rel-
evance is supported by the presence of four of them in
another brain region. Our approach was less efficient in
isolating TCCs from inactive lesions, which may indicate
reduced recirculation through the CSF of T cells from
older lesions or again higher exhaustion of these TCCs.
The functional characterization of brain-infiltrating CD4+
and CD8+ TCCs demonstrated a predominance of T cells
that release Th2 cytokines and support B-cell proliferation
and antibody production as well as a minority of T cells
secreting Th1 cytokines that might also contribute to the
humoral response by promoting B-cell activation. Despite
the high intrathecal IgG production in this patient, this
was an unexpected finding in the context of MS. Not only
is the prevailing concept in the field that autoreactive Th1
and Th17 cells are the main drivers of disease, but fur-
thermore a protective rather than a pathogenic role has
been ascribed to Th2 cells suggesting that immune devia-
tion from Th1 toward Th2 cells is generally a promising
therapeutic approach.41–43 Although none of the currently
approved therapies for MS targets explicitly T cells that
secrete specific proinflammatory cytokines, several lines of
evidence in preclinical and clinical studies suggest that the
established first-line therapies IFN-beta and glatiramer
acetate increase the production of anti-inflammatory
cytokines like IL-4 and suppress the production of pro-
inflammatory cytokines.44 However, it has also already
been proposed that Th2 cells can be pathogenic in MS,45
and in a MOG-induced marmoset experimental autoim-
mune encephalomyelitis (EAE) model immune deviation
from Th1 to Th2 cells after tolerization with soluble
MOG led to increased production of pathogenic autoanti-
bodies and severe EAE.46
Finally, an interesting observation from a clinical point
of view is that T cells releasing Th2 cytokines are also
predominant in the CSF infiltrate of this pattern II patient,
while we found that the expected Th1 cytokine secretion
dominated the CSF cells in a pattern III patient. The release
of Th2 cytokines by CSF-infiltrating T cells in combination
with other CSF markers such as CXCL13, CiC C1q and IgG
index might allow the identification of demyelinating pat-
tern II patients, which would be very useful for choosing
the best treatment options. As an important next step it will
be of interest to identify the target autoantigens for Th2
and Tc2 cells in pattern II MS.
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